Clinical Characteristics and Risk Factors of Ovarian Reserve Decreases in Women with Crohn's Disease: a Case-control Study

Overview

Journal J Ovarian Res

Publisher Biomed Central

Specialties Gynecology & Obstetrics
Reproductive Medicine

Date 2023 Feb 8

PMID 36750949

Authors

Peng Xiang

Jia-Yin Yao

Xiao-Lan Li

Min Zhang

Pin-Jin Hu

Min Zhi

Affiliations

Soon will be listed here.

Abstract

Background: Crohn's disease (CD), often occurring in women of child-bearing age, can decline the fertility rate. However, whether it reduces ovarian reserve has been rarely reported. This study aimed to evaluate the ovarian reserve in women with CD from the perspective of anti-Müllerian hormone (AMH), and explore the factors that can decrease ovarian reserve.

Methods: A case-control retrospective study was designed. We analyzed the AMH levels in a total of 135 CD women and 878 healthy controls. Through propensity score matching, the subjects were assigned in a ratio of 1:3 to CD group (n = 121) and control group (n = 324). Both groups shared similar basic characteristics, like age, body mass index and smoking status. Serum AMH levels were measured by chemiluminescence.

Results: The AMH level in the CD group was significantly lower than that in the control group (2.17 ± 2.23 μg/L vs 3.95 ± 2.01 μg/L, 95%CI [1.34-2.21], P < 0.001). In both groups, the AMH levels decreased as age increased, but without between-group difference in the decreasing rate (P = 0.639). Multivariate analysis showed that age > 30 years (OR, 2.905; 95%CI [1.053-8.531], P = 0.017), disease activity (OR,4.314; 95%CI [1.561-12.910], P = 0.002) and thalidomide use (OR,12.628; 95%CI [4.351 -42.820], P < 0.001) were independent risk factors associated with decreased ovarian reserve (AMH<1.1μg/L).

Conclusion: Ovarian reserve is lower in CD women than in healthy women. Age, CD activity and medication of thalidomide are risk factors that can aggravate the decline of ovarian reserve.

Citing Articles

Inhibin B and antiMüllerian hormone as surrogate markers of fertility in male and female Crohn's disease patients: a case-control study.

Gutierrez A, Munoz-Perez R, Zapater P, Mira C, Rodriguez A, Sempere-Robles L Front Med (Lausanne). 2024; 11:1374603.

PMID: 38725465 PMC: 11080652. DOI: 10.3389/fmed.2024.1374603.

References

Mountifield R, Bampton P, Prosser R, Muller K, Andrews J . Fear and fertility in inflammatory bowel disease: a mismatch of perception and reality affects family planning decisions. Inflamm Bowel Dis. 2008; 15(5):720-5. DOI: 10.1002/ibd.20839. View

Moens A, van der Woude C, Julsgaard M, Humblet E, Sheridan J, Baumgart D . Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study. Aliment Pharmacol Ther. 2019; 51(1):129-138. DOI: 10.1111/apt.15539. View

Freour T, Miossec C, Bach-Ngohou K, Dejoie T, Flamant M, Maillard O . Ovarian reserve in young women of reproductive age with Crohn's disease. Inflamm Bowel Dis. 2011; 18(8):1515-22. DOI: 10.1002/ibd.21872. View

Meduri G, Massin N, Guibourdenche J, Bachelot A, Fiori O, Kuttenn F . Serum anti-Müllerian hormone expression in women with premature ovarian failure. Hum Reprod. 2006; 22(1):117-23. DOI: 10.1093/humrep/del346. View

Speirs A . Thalidomide and congenital abnormalities. Lancet. 1962; 1(7224):303-5. DOI: 10.1016/s0140-6736(62)91248-5. View

Winger E, Reed J, Ashoush S, Ahuja S, El-Toukhy T, Taranissi M . Treatment with adalimumab (Humira) and intravenous immunoglobulin improves pregnancy rates in women undergoing IVF. Am J Reprod Immunol. 2008; 61(2):113-20. DOI: 10.1111/j.1600-0897.2008.00669.x. View

Selinger C, Eaden J, Selby W, Brian Jones D, Katelaris P, Chapman G . Inflammatory bowel disease and pregnancy: lack of knowledge is associated with negative views. J Crohns Colitis. 2012; 7(6):e206-13. DOI: 10.1016/j.crohns.2012.09.010. View

. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil Steril. 2015; 103(3):e9-e17. DOI: 10.1016/j.fertnstert.2014.12.093. View

Van Assche G, Dignass A, Reinisch W, van der Woude C, Sturm A, De Vos M . The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. J Crohns Colitis. 2010; 4(1):63-101. DOI: 10.1016/j.crohns.2009.09.009. View

10.

Qu J, Nisolle M, Donnez J . Expression of transforming growth factor-alpha, epidermal growth factor, and epidermal growth factor receptor in follicles of human ovarian tissue before and after cryopreservation. Fertil Steril. 2000; 74(1):113-21. DOI: 10.1016/s0015-0282(00)00549-5. View

11.

Wallace W, Kelsey T . Human ovarian reserve from conception to the menopause. PLoS One. 2010; 5(1):e8772. PMC: 2811725. DOI: 10.1371/journal.pone.0008772. View

12.

Senates E, Colak Y, Erdem E, Yesil A, Coskunpinar E, Sahin O . Serum anti-Müllerian hormone levels are lower in reproductive-age women with Crohn's disease compared to healthy control women. J Crohns Colitis. 2012; 7(2):e29-34. DOI: 10.1016/j.crohns.2012.03.003. View

13.

Selinger C, Ghorayeb J, Madill A . What Factors Might Drive Voluntary Childlessness (VC) in Women with IBD? Does IBD-specific Pregnancy-related Knowledge Matter?. J Crohns Colitis. 2016; 10(10):1151-8. DOI: 10.1093/ecco-jcc/jjw078. View

14.

Riggs R, Duran E, Baker M, Kimble T, Hobeika E, Yin L . Assessment of ovarian reserve with anti-Müllerian hormone: a comparison of the predictive value of anti-Müllerian hormone, follicle-stimulating hormone, inhibin B, and age. Am J Obstet Gynecol. 2008; 199(2):202.e1-8. DOI: 10.1016/j.ajog.2008.05.004. View

15.

Lee S, Crowe M, Seow C, Kotze P, Kaplan G, Metcalfe A . The impact of surgical therapies for inflammatory bowel disease on female fertility. Cochrane Database Syst Rev. 2019; 7:CD012711. PMC: 6647933. DOI: 10.1002/14651858.CD012711.pub2. View

16.

Duricova D, Burisch J, Jess T, Gower-Rousseau C, Lakatos P . Age-related differences in presentation and course of inflammatory bowel disease: an update on the population-based literature. J Crohns Colitis. 2014; 8(11):1351-61. DOI: 10.1016/j.crohns.2014.05.006. View

17.

Franks M, Macpherson G, Figg W . Thalidomide. Lancet. 2004; 363(9423):1802-11. DOI: 10.1016/S0140-6736(04)16308-3. View

18.

Vasiliauskas E, Kam L, Hassard P, Papadakis K, Yang H, Zeldis J . An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology. 1999; 117(6):1278-87. DOI: 10.1016/s0016-5085(99)70277-5. View

19.

Clowse M, Harward L, Criscione-Schreiber L, Pisetsky D, Copland S . Anti-Müllerian hormone: a better marker of ovarian damage from cyclophosphamide. Arthritis Rheum. 2012; 64(5):1305-10. DOI: 10.1002/art.34431. View

20.

Sharma G, Dubey P, Kumar G . Effects of IGF-1, TGF-alpha plus TGF-beta1 and bFGF on in vitro survival, growth and apoptosis in FSH-stimulated buffalo (Bubalis bubalus) preantral follicles. Growth Horm IGF Res. 2010; 20(4):319-25. DOI: 10.1016/j.ghir.2010.05.001. View